scispace - formally typeset
H

Hennie R. Hoogenboom

Researcher at Maastricht University

Publications -  85
Citations -  18195

Hennie R. Hoogenboom is an academic researcher from Maastricht University. The author has contributed to research in topics: Phage display & Antibody. The author has an hindex of 51, co-authored 85 publications receiving 17946 citations.

Papers
More filters
Journal Article

Human Single-Chain Fv Antibodies to MUC1 Core Peptide Selected from Phage Display Libraries Recognize Unique Epitopes and Predominantly Bind Adenocarcinoma

TL;DR: Five human single-chain Fv antibodies specific for the MUC1 variable number of tandem repeats region are isolated by in vitro selection from a large naive phage antibody library containing over 6 x 10(9) different scFv antibodies.
Journal ArticleDOI

A sensitive immunoassay for rat fatty acid translocase (CD36) using phage antibodies selected on cell transfectants: abundant presence of fatty acid translocase/CD36 in cardiac and red skeletal muscle and up-regulation in diabetes

TL;DR: The rat membrane protein fatty acid translocase (FAT), which shows sequence similarity to human CD36 (a membrane protein supposedly involved in a variety of membrane processes), is implicated in the transport of long-chain fatty acids across cellular membranes and phage display technology has been succesfully applied for direct selection of antibodies that recognize selected membrane proteins in their natural context.
Journal ArticleDOI

Model systems to study the parameters determining the success of phage antibody selections on complex antigens.

TL;DR: Two model selection systems based on phage antibodies directed to the tumour antigen epithelial glycoprotein-2 and a model based on a phage antibody directed against the endothelial cell inducible adhesion molecule E-selectin are described.
Journal ArticleDOI

Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas

TL;DR: This small and partially humanized recombinant bispecific antibody fragment may be valuable for T‐cell–based immunotherapeutical treatment protocols, retargeting activated peripheral blood T lymphocytes to lyse various human carcinomas in vivo.